Yıl: 2021 Cilt: 32 Sayı: 3 Sayfa Aralığı: 302 - 312 Metin Dili: İngilizce DOI: 10.5152/tjg.2021.20062 İndeks Tarihi: 24-05-2022

The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade

Öz:
Background: The true prevalence of non-alcoholic fatty liver disease (NAFLD) is unknown in Turkey due to a lack of population-based studies. The aim of this study was (i) to determine the overall and region-specific prevalence of NAFLD in Turkey; (ii) to analyze the factors associated with the prevalence; and (iii) to determine the nationwide change in the prevalence of NAFLD in the last decade. Methods: The 10-year data (2007-2016) of 113 239 apparently healthy subjects visiting the check-up clinics of Acibadem Hospitals Group were retrospectively analyzed. A subgroup of patients (n=8120) statistically representing the bigger cohort was selected. The prevalence was analyzed according to ultrasound findings, age, sex, body mass index (BMI), geographical region, and time periods trisected as 2007-2010, 2011-2013, and 2014-2016. Results: The overall prevalence of NAFLD in Turkey was found to be 48.3%. It was highest among people >50 years of age (65.6%), male sex (64.0%), with a BMI >25 kg/m2 (63.5%), and in Central and Eastern Anatolia regions (57.1% and 55.7%, respectively). The prevalence of NAFLD was 43.5% between 2007 and 2010, 47.6% between 2011 and 2013, and 53.1% between 2014 and 2016, and the rate of increase was 22%. Multivariate analysis showed that male sex, serum alanine aminotransferase level, older age, BMI, type-II diabetes mellitus, hypertension, and dyslipidemia were independent factors associated with NAFLD. Conclusion: NAFLD is a highly prevalent disease affecting almost half of the Turkish population (48.3%). We are faced with a dramatic increase in NAFLD prevalence in the past 10 years.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-2682. [CrossRef]
  • 2. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. [CrossRef]
  • 3. Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007;47(2):239-244. [CrossRef]
  • 4. Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation. 2000;69(11):2410-2415. [CrossRef]
  • 5. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a metaanalysis. Hepatology. 2011;54(3):1082-1090. [CrossRef]
  • 6. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42(1):44-52. [CrossRef]
  • 7. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-1395. [CrossRef]
  • 8. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38(10):954-961. [CrossRef]
  • 9. Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver diseases. Hepatol Int. 2020;14(6):889-919. [CrossRef]
  • 10. Celebi S, AH, Mengucuk E, Deveci SH, Acık Y, Bahcecioglu İH. Epidemic features of nonalcoholic fatty liver in urban community of Elazıg. Akad Gastroenteroloji Derg. 2006;5:41-46.
  • 11. Kaya E, Demir D, Alahdab YO, Yilmaz Y. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. Eur J Gastroenterol Hepatol. 2016;28(11):1264-1267. [CrossRef]
  • 12. Okur G, Karacaer Z. The prevalence of non-alcoholic fatty liver disease in healthy young persons. North Clin Istanb. 2016;3(2):111- 117. [CrossRef]
  • 13. Sezgin O, Akpınar H, Özer B, Törüner M, Bal K, Bor S. Kapadokya Kohort Çalışması OzerB. Kapadokya Kohort Çalışması: Gastrointestinal Hastalıkların ve Ultrasonografik Bulgularının Sıklığı. 35. Ulusal Gastroenteroloji Haftası. 2018; ;SS-085;161.
  • 14. Kozan O, Oguz A, Abaci A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr. 2007;61(4):548-553. [CrossRef]
  • 15. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28(2):169-180. [CrossRef]
  • 16. Satman I, Yilmaz T, Sengül A, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care. 2002;25(9):1551- 1556. [CrossRef]
  • 17. Caballería L, Pera G, Auladell MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol. 2010;22(1):24-32. [CrossRef]
  • 18. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285. [CrossRef]
  • 19. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9(8):616- 622. [CrossRef]
  • 20. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121(3):710-723. [CrossRef]
  • 21. Chen CH, Huang MH, Yang JC, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol. 2007;22(9):1482-1489. [CrossRef]
  • 22. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43(3):508-514. [CrossRef]
  • 23. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722-728. [CrossRef]
  • 24. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124(1):71-79. [CrossRef]
  • 25. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int Off J Int Assoc Study Liver. 2009;29(1):113-119. [CrossRef]
  • 26. Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Phys India. 2009;57:205-210.
  • 27. Colicchio P, Tarantino G, del Genio F, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab. 2005;49(5):289-295. [CrossRef]
  • 28. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600-606. [CrossRef]
  • 29. Demir M, Deyneli O, Yılmaz Y. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: a transient elastography study. Turk J Gastroenterol. 2019;30(3):266-270. [CrossRef]
  • 30. Degertekin B, Tozun N, Demir F. Determination of the upper limits of normal serum alanine aminotransferase (ALT) level in healthy Turkish population. Hepatology Forum. 2020;2:44-47. [CrossRef]
APA Degertekin B, Tozun A, DEMİR F, SÖYLEMEZ G, PARKAN Ş, GÜRTAY E, MUTLU D, TORAMAN M, Seymenoglu T (2021). The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. , 302 - 312. 10.5152/tjg.2021.20062
Chicago Degertekin Bulent,Tozun Ayse Nurdan,DEMİR Figen,SÖYLEMEZ Gizem,PARKAN Şirin,GÜRTAY Ezgi,MUTLU Deniz,TORAMAN Meltem,Seymenoglu Tolga Hayrettin The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. (2021): 302 - 312. 10.5152/tjg.2021.20062
MLA Degertekin Bulent,Tozun Ayse Nurdan,DEMİR Figen,SÖYLEMEZ Gizem,PARKAN Şirin,GÜRTAY Ezgi,MUTLU Deniz,TORAMAN Meltem,Seymenoglu Tolga Hayrettin The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. , 2021, ss.302 - 312. 10.5152/tjg.2021.20062
AMA Degertekin B,Tozun A,DEMİR F,SÖYLEMEZ G,PARKAN Ş,GÜRTAY E,MUTLU D,TORAMAN M,Seymenoglu T The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. . 2021; 302 - 312. 10.5152/tjg.2021.20062
Vancouver Degertekin B,Tozun A,DEMİR F,SÖYLEMEZ G,PARKAN Ş,GÜRTAY E,MUTLU D,TORAMAN M,Seymenoglu T The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. . 2021; 302 - 312. 10.5152/tjg.2021.20062
IEEE Degertekin B,Tozun A,DEMİR F,SÖYLEMEZ G,PARKAN Ş,GÜRTAY E,MUTLU D,TORAMAN M,Seymenoglu T "The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade." , ss.302 - 312, 2021. 10.5152/tjg.2021.20062
ISNAD Degertekin, Bulent vd. "The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade". (2021), 302-312. https://doi.org/10.5152/tjg.2021.20062
APA Degertekin B, Tozun A, DEMİR F, SÖYLEMEZ G, PARKAN Ş, GÜRTAY E, MUTLU D, TORAMAN M, Seymenoglu T (2021). The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. Turkish Journal of Gastroenterology, 32(3), 302 - 312. 10.5152/tjg.2021.20062
Chicago Degertekin Bulent,Tozun Ayse Nurdan,DEMİR Figen,SÖYLEMEZ Gizem,PARKAN Şirin,GÜRTAY Ezgi,MUTLU Deniz,TORAMAN Meltem,Seymenoglu Tolga Hayrettin The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. Turkish Journal of Gastroenterology 32, no.3 (2021): 302 - 312. 10.5152/tjg.2021.20062
MLA Degertekin Bulent,Tozun Ayse Nurdan,DEMİR Figen,SÖYLEMEZ Gizem,PARKAN Şirin,GÜRTAY Ezgi,MUTLU Deniz,TORAMAN Meltem,Seymenoglu Tolga Hayrettin The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. Turkish Journal of Gastroenterology, vol.32, no.3, 2021, ss.302 - 312. 10.5152/tjg.2021.20062
AMA Degertekin B,Tozun A,DEMİR F,SÖYLEMEZ G,PARKAN Ş,GÜRTAY E,MUTLU D,TORAMAN M,Seymenoglu T The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. Turkish Journal of Gastroenterology. 2021; 32(3): 302 - 312. 10.5152/tjg.2021.20062
Vancouver Degertekin B,Tozun A,DEMİR F,SÖYLEMEZ G,PARKAN Ş,GÜRTAY E,MUTLU D,TORAMAN M,Seymenoglu T The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. Turkish Journal of Gastroenterology. 2021; 32(3): 302 - 312. 10.5152/tjg.2021.20062
IEEE Degertekin B,Tozun A,DEMİR F,SÖYLEMEZ G,PARKAN Ş,GÜRTAY E,MUTLU D,TORAMAN M,Seymenoglu T "The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade." Turkish Journal of Gastroenterology, 32, ss.302 - 312, 2021. 10.5152/tjg.2021.20062
ISNAD Degertekin, Bulent vd. "The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade". Turkish Journal of Gastroenterology 32/3 (2021), 302-312. https://doi.org/10.5152/tjg.2021.20062